| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA875: Semaglutide for managing overweight and obesity |
|
Medicine details |
|
| Medicine name | semaglutide (Wegovy®) |
| Formulation | 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and 2.4 mg solution for injection in pre-filled pen |
| Reference number | 4228 |
| Indication | Adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of ≥30 kg/m2 (obesity), or ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity. |
| Company | Novo Nordisk Ltd |
| BNF chapter | Central nervous system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 06/01/2022 |
| NICE guidance | |